AbbVie Forecast, price target & analysts
AbbVie Target price 2025 - Analyst rating & recommendation
AbbVie Classifications & Recommendation:
AbbVie Price Target
| Target Price | $207.74 |
| Price | $202.08 |
| Potential |
2.80%
register free of charge
|
| Number of Estimates | 23 |
|
23 Analysts have issued a price target AbbVie 2026 .
The average AbbVie target price is $207.74.
This is
2.80%
register free of charge
$239.00
18.27%
register free of charge
$165.00
18.35%
register free of charge
|
|
| A rating was issued by 29 analysts: 19 Analysts recommend AbbVie to buy, 10 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the AbbVie stock has an average upside potential 2026 of
2.80%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 56.33 | 59.42 |
| 3.71% | 5.47% | |
| EBITDA Margin | 44.40% | 48.75% |
| 9.95% | 9.80% | |
| Net Margin | 7.49% | 20.74% |
| 15.28% | 176.93% |
20 Analysts have issued a sales forecast AbbVie 2025 . The average AbbVie sales estimate is
This results in the following potential growth metrics:
11 Analysts have issued an AbbVie EBITDA forecast 2025. The average AbbVie EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 AbbVie Analysts have issued a net profit forecast 2025. The average AbbVie net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 2.39 | 6.98 |
| 12.13% | 192.05% | |
| P/E | 28.95 | |
| EV/Sales | 7.05 |
7 Analysts have issued a AbbVie forecast for earnings per share. The average AbbVie <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the AbbVie stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Current AbbVie Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Guggenheim | Buy ➜ Buy | Unchanged | Feb 03 2025 |
| UBS | Neutral ➜ Neutral | Unchanged | Feb 03 2025 |
| Citigroup | Buy ➜ Buy | Unchanged | Feb 03 2025 |
| Truist Securities | Buy ➜ Buy | Unchanged | Feb 03 2025 |
| Raymond James | Outperform ➜ Outperform | Unchanged | Feb 03 2025 |
| Morgan Stanley | Overweight ➜ Overweight | Unchanged | Feb 03 2025 |
| BMO Capital | Outperform ➜ Outperform | Unchanged | Feb 03 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Guggenheim: Buy ➜ Buy
|
Feb 03 2025 |
|
Unchanged
UBS: Neutral ➜ Neutral
|
Feb 03 2025 |
|
Unchanged
Citigroup: Buy ➜ Buy
|
Feb 03 2025 |
|
Unchanged
Truist Securities: Buy ➜ Buy
|
Feb 03 2025 |
|
Unchanged
Raymond James: Outperform ➜ Outperform
|
Feb 03 2025 |
|
Unchanged
Morgan Stanley: Overweight ➜ Overweight
|
Feb 03 2025 |
|
Unchanged
BMO Capital: Outperform ➜ Outperform
|
Feb 03 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
